Riksbank minutes: Governor Thedéen said a major risk is that sustained supply-side cost increases linked to global geopolitical tensions could interact with a strengthening economy.

On Nov 9 Russian presidential spokesperson Dmitry Peskov said the upcoming Abu Dhabi talks on Ukraine are a US‑mediated tripartite meeting and that European states already have channels to communicate with the US and Ukraine. On the same day European Commission President Von der Leyen told Ukrainian President Zelenskiy the EU will attend the Abu Dhabi talks with its partners. A US official said on Nov 2 (ET) the US will hold tripartite talks with Ukraine and Russia in Abu Dhabi on Nov 10‑11.

1. Tigermed (03347.HK): The company plans to sell its control over its subsidiary, Fangda Holdings, and divest Fangda Holdings' overseas laboratory business. 2. Datang Gold (08299.HK): The company expects total profit attributable to owners of the company to be approximately HK$208 million for the six months ended September 30, 2026. 3. Guangzhou Baiyunshan Pharmaceutical (00874.HK): Guangzhou Pharmaceutical plans to introduce strategic investors and conduct a private placement of shares, with an expected fundraising amount not exceeding RMB 6 billion. 4. Agile Group (03383.HK): The total pre-sale amount for the first ten months of 2026 was approximately RMB 5.18 billion, corresponding to a construction area of approximately 587,000 square meters, with an average price of RMB 8,825 per square meter. 5. Q Technology (01478.HK): In October 2026, the group's mobile phone sales volume was 38.845 million units, a decrease of 22.6% month-on-month and 37.7% year-on-year; among which, camera module sales volume was 23.904 million units, a decrease of 34.2% month-on-month and 45.7% year-on-year. 6. COSCO Shipping Energy Transportation (01138.HK) announced that its wholly-owned subsidiary, Hainan Haineng, signed a contract with Dalian Shipbuilding Industry Co., Ltd. to build four VLCC crude oil tankers, with a total contract price of RMB 3.793 billion and a total investment of approximately RMB 3.829 billion. 7. Rongchang Biotechnology (09995.HK) announced that it signed a "Licensing Agreement" with Yantai Rongchang Pharmaceutical, obtaining a global exclusive license for pan-RAS(ON) small molecule inhibitors. The company will pay an initial payment of RMB 50 million, with maximum milestone payments of RMB 4.87 billion, and royalties based on 3%-7% of annual net sales. 8. Longyuan Power (00916.HK): In the first 10 months of 2026, the company's cumulative power generation reached 64.128 million MWh, a year-on-year increase of 3.18%; in October, on a consolidated basis, the company's power generation reached 6.8742 million MWh, a year-on-year increase of 22.64%. 9. WuXi AppTec (02359.HK) announced: On November 9, 2026, we learned that the U.S. Department of Defense decided to remove WuXi AppTec from the CMC list under Item 1260H. 10. Ribobio-B (06938.HK) submitted a Phase I clinical trial application for its dual-target drug SR122 injection for the treatment of mixed dyslipidemia and severe hypertriglyceridemia.